Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-2617

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71335-2617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line chart showing the percentage of patients achieving systolic blood pressure (SBP) below 140 mmHg plotted against baseline SBP levels from 140 to 180 mmHg. Four groups are compared: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The Valsartan-HCTZ combination shows the highest percentage achieving target SBP.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph depicting the percentage of patients achieving diastolic blood pressure (DBP) less than 90 mmHg as a function of baseline DBP (mmHg). It compares four treatments: valsartan-hydrochlorothiazide 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo, with percentage on the y-axis and baseline DBP on the x-axis.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line graph compares the percentage of patients with baseline systolic blood pressure (SBP) values under 130 mmHg across different baseline SBP levels. It features four data series representing Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The y-axis shows the percentage achieving SBP below 130 mmHg, and the x-axis shows baseline SBP in mmHg.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line graph depicting the percentage of patients achieving a diastolic blood pressure (DBP) less than 80 mmHg across different baseline DBP levels (90 to 110 mmHg). It compares responses to Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, using distinct markers for each treatment group.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure of valsartan, an active ingredient in the drug product valsartan and hydrochlorothiazide. The diagram shows the molecular arrangement with rings and side chains typical of valsartan.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure of valsartan and hydrochlorothiazide, depicting the molecular arrangement of atoms and bonds for this combination drug.*

FDA Label Image

Label (Lbl713352617)

Label for Valsartan and Hydrochlorothiazide Tablets USP, 160 mg/12.5 mg strength, manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., and repackaged by Bryant Ranch Prepack, Inc. The label includes storage instructions, packaging quantity of 30 tablets, Rx only status, and a QR code for patient information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.